News

The EXTEND and EPITHET trials selected patients by perfusion mismatch rather than the less sensitive noncontrast computed tomography, the findings providing reassurance of consistency for thrombolysis-induced reperfusion.

The vascular neurologist at Memorial Hermann Medical Group discusses how stroke care has been affected throughout the COVID-19 pandemic.

Veronica Hood, PhD, of the Dravet Syndrome Foundation, details the recently accepted ICD-10 codes for Dravet syndrome and what benefit they bring to patients.

The Mission Thrombectomy 2020+ group outlined a plan to increase the awareness, accessibility, and action for mechanical thrombectomy utilization for patients with stroke globally.

The drug joins Cerebryx as the second FDA-approved fosphenytoin for benzodiazepine-refractory status epilepticus.

New recommendations were developed for the use of rituximab, eculizumab, and methotrexate, as well as updates on previous recommendations for thymectomy.

The director of Translational Research and Clinical Trials Epilepsy at NYU Grossman School of Medicine discussed the groundwork done with the Human Epilepsy Project for a recent analysis.

An analysis from English and Scottish stroke centers provides physicians a new view of the trends and outcomes of patients with COVID-19 who experience stroke.

The Cleveland Clinic researcher discussed the unknowns about Parkinson disease dementia and what has been previously observed in clinical studies.

Here's what is coming soon to NeurologyLive.

A tertiary analysis of the AVERT study reveals divergent findings suggesting that mortality increases with VEM compared to usual care after restricting follow-up to 14 days.

The associate professor of neurology at Washington University in St. Louis detailed a number of key presentations on advances and novel medications in the sleep space.

The research coordinator of the Dravet Foundation provided background on the new ICD-10 codes announced for Dravet syndrome and how they came about.

There is no evidence yet that SARS-CoV-2 can pass the blood-brain barrier, though its effects on the barrier may be intensified in those with dementia.

Neurology News Network for the week ending November 7, 2020.